APPLICATION
ANDA209796
TYPE
ANDA
ORIGINAL APPROVAL
2020-02-24
LATEST ACTION
2024-05-31
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription
Products
CLOBAZAMPrescription
CLOBAZAM 2.5MG/ML · SUSPENSION · ORAL
Approval history
2024-05-31Labeling · Supplement 3 · standardAP
2023-05-12Labeling · Supplement 2 · standardAP
2021-10-20Labeling · Supplement 1 · standardAP
2020-02-24UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.